Erratum: Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma (JCI Insight (2018) 3:16 (e122204) DOI: 10.1172/jci.insight.122204)

It has been brought to the authors’ attention that the STR profile of the head and neck squamous cell carcinoma line UT-SCC-54C presented in Supplemental Table 1 is markedly different from that of UT-SCC-54A and UT-SCC-54B, which originated from the same patient. Upon further investigation, the authors have determined that the UT-SCC-54C cultures used in this study almost exclusively comprise colon cancer–derived HCT116 cells, as demonstrated by STR, gene expression, and mutation profiling. The authors regret contamination of the UT-SCC-54C line reported here and confirm that uncontaminated UT-SCC-54C cultures are available from earlier frozen stocks. The authors have stated that the conclusions of the study are not affected.